2003
Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study
Krumholz HM, Gross CP, Peterson ED, Barron HV, Radford MJ, Parsons LS, Every NR. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study. American Heart Journal 2003, 146: 839-847. PMID: 14597933, DOI: 10.1016/s0002-8703(03)00408-3.Peer-Reviewed Original ResearchConceptsCooperative Cardiovascular ProjectRandomized trialsExclusion criteriaEligibility criteriaMortality rateClinical practiceKillip class III/IVClass III/IVOccluded Coronary Arteries (GUSTO-I) trialCoronary Arteries trialHospital mortality rateMyocardial infarction careTrial eligibility criteriaHigh mortality rateRetrospective registryBaseline characteristicsClinical characteristicsElderly patientsOlder patientsCCP patientsClinical presentationClinical eventsMyocardial infarctionHealthy cohortHospital characteristics
1995
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction
Kalish S, Gurwitz J, Krumholz H, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Journal Of General Internal Medicine 1995, 10: 321-330. PMID: 7562123, DOI: 10.1007/bf02599951.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsTissue plasminogen activatorAcute myocardial infarctionAdditional quality-adjusted life yearMyocardial infarctionGUSTO trialThrombolytic therapyOne-year mortality dataOccluded Coronary Arteries (GUSTO-I) trialMortality dataPlasminogen activatorLong-term medical costsCoronary Arteries trialOne-year mortalityUse of streptokinaseInferior wall infarctionCost-effective therapyCost-effectiveness modelDecision analysis modelSurvival benefitSymptom onsetClinical outcomesRelative survival advantageThrombolytic agentsSurvival advantage